

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 970
TO BE ANSWERED ON 29TH APRIL, 2016
TREATMENT IN TUBERCULOSIS**

970. SHRI A. ARUNMOZHITHEVAN:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Indian Tuberculosis policy continues to recommend the use of Category II treatment regimens containing streptomycin despite recommendations of drug susceptibility test for those at risk of MDR TB; and
- (b) if so, the details thereof and the reaction of the Government thereto?

**ANSWER
THE MINISTER OF HEALTH AND FAMILY WELFARE
(SHRI JAGAT PRAKASH NADDA)**

(a) & (b): Retreatment or Previously treated TB patients, who have taken anti TB drugs for one month or more in the past, and are now diagnosed with Tuberculosis, are given category II treatment regimen under Revised national Tuberculosis Control Programme (RNTCP) provided they are not suffering from MDR TB.

However under RNTCP these patients are considered as at risk of MDR TB and are therefore also required to undergo baseline Drug Susceptibility Testing (DST) so that based on the DST result appropriate treatment is continued.

.....